Novel approaches to the management of myeloma

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Standard therapy for multiple myeloma, which accounts for 10% of all hematologic malignancies, has been autologous stem cell transplantation (ASCT), alkylator-based chemotherapy, and corticosteroids. Several advances have been made in the treatment of multiple myeloma over the past decade, especially the arrival of new, active agents such as thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid). These have shown significant clinical activity as single agents. Trials are ongoing to incorporate these new agents into the various stages of treatment and to combine them with other effective treatment modalities, including ASCT.

Original languageEnglish (US)
Pages (from-to)621-625
Number of pages5
JournalOncology
Volume19
Issue number5
StatePublished - 2005

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Thalidomide
Alkylating Agents
Hematologic Neoplasms
Therapeutics
Adrenal Cortex Hormones
Drug Therapy
Bortezomib
lenalidomide

ASJC Scopus subject areas

  • Oncology

Cite this

Novel approaches to the management of myeloma. / Rajkumar, S Vincent.

In: Oncology, Vol. 19, No. 5, 2005, p. 621-625.

Research output: Contribution to journalArticle

@article{3da301a33f46485fa1196c4e7c3a9362,
title = "Novel approaches to the management of myeloma",
abstract = "Standard therapy for multiple myeloma, which accounts for 10{\%} of all hematologic malignancies, has been autologous stem cell transplantation (ASCT), alkylator-based chemotherapy, and corticosteroids. Several advances have been made in the treatment of multiple myeloma over the past decade, especially the arrival of new, active agents such as thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid). These have shown significant clinical activity as single agents. Trials are ongoing to incorporate these new agents into the various stages of treatment and to combine them with other effective treatment modalities, including ASCT.",
author = "Rajkumar, {S Vincent}",
year = "2005",
language = "English (US)",
volume = "19",
pages = "621--625",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "5",

}

TY - JOUR

T1 - Novel approaches to the management of myeloma

AU - Rajkumar, S Vincent

PY - 2005

Y1 - 2005

N2 - Standard therapy for multiple myeloma, which accounts for 10% of all hematologic malignancies, has been autologous stem cell transplantation (ASCT), alkylator-based chemotherapy, and corticosteroids. Several advances have been made in the treatment of multiple myeloma over the past decade, especially the arrival of new, active agents such as thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid). These have shown significant clinical activity as single agents. Trials are ongoing to incorporate these new agents into the various stages of treatment and to combine them with other effective treatment modalities, including ASCT.

AB - Standard therapy for multiple myeloma, which accounts for 10% of all hematologic malignancies, has been autologous stem cell transplantation (ASCT), alkylator-based chemotherapy, and corticosteroids. Several advances have been made in the treatment of multiple myeloma over the past decade, especially the arrival of new, active agents such as thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid). These have shown significant clinical activity as single agents. Trials are ongoing to incorporate these new agents into the various stages of treatment and to combine them with other effective treatment modalities, including ASCT.

UR - http://www.scopus.com/inward/record.url?scp=22144433731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144433731&partnerID=8YFLogxK

M3 - Article

C2 - 15948290

AN - SCOPUS:22144433731

VL - 19

SP - 621

EP - 625

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5

ER -